"Heterogeneity of treatment effect on patients' long-term outcome according to pathological response type in neoadjuvant RCTs for breast cancer."

CONCLUSION: We reported new evidence that contributes to explaining the poor surrogacy value of pCR at trial-level in neoadjuvant RCTs for early-BC.PMID:38244459 | PMC:PMC10831306 | DOI:10.1016/j.breast.2024.103672

Source: Breast - January 20, 2024 Category: Cancer & Oncology Authors: Laura Pala Isabella Sala Eleonora Pagan Tommaso De Pas Emma Zattarin Chiara Catania Emilia Cocorocchio Giovanna Rossi Daniele Laszlo Giovanni Ceresoli Jacopo Canzian Elena Valenzi Vincenzo Bagnardi Fabio Conforti Source Type: research